USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Shire has billed its third-quarter results as record-breaking, but markets are less convinced as the Ireland-incorporated company’s share price has dropped by 2.1% since they were presented on Tuesday. 1 November 2016
Third Rock Ventures is to spend proceeds from its latest $616 million fundraising drive on investing in healthcare firms with a particular emphasis on innovative product engine companies in areas including oncology, immunology, neurological disorders, cardiovascular disease and rare genetic diseases. 1 November 2016
The share price of US drugmaker AbbVie was in decline again on Monday morning after revenue levels in its third quarter results fell below analysts’ predictions. 31 October 2016
US healthcare giant Johnson & Johnson reported sales of $17.8 billion for the third quarter of 2016, a 4.2% increase compared to the same period last year. 18 October 2016
Around 1,000 jobs are to go at Danish diabetes giant Novo Nordisk, which amounts to nearly 2.4% of its total global workforce.
This action has been described in a statement as “one of several actions taken to reduce operating costs as the company faces a challenging competitive environment in 2017, especially in its large US market.” 29 September 2016
Werner Baumann, management board chairman at German pharma and crop sciences major Bayer, is confident that the company can deliver after raising the combined peak annual sales potential of five recently launched pharmaceutical products by a third. 20 September 2016
In our weekly expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, explains why we can expect mid-market companies to press on with their expansion through strategic transactions for the remainder of 2016. 20 September 2016
Belgian drugmaker Ablynx has posted 2016 half-yearly financial results showing its revenue and grant income rose by 39% compared to 2015’s first six months. 25 August 2016
Hikma Pharmaceuticals saw its profits drop by 14% in the first half of 2016 compared to last year, but the Jordan-based drugmaker has reiterated its full year revenue guidance. 24 August 2016
Canada's battered drugmaker Valeant Pharmaceuticals International has had some good news in the shape of lender consent for an amendment to its credit facility, but it comes in the midst of accusations from its former shareholder T Rowe Price. 22 August 2016
The market for respiratory drugs will grow from its 2015 size of $28.1 billion to $46.6 billion by 2022 at a compound annual growth rate (CAGR) of 7.5%, according to business intelligence provider GBI Research. 18 August 2016
In our weekly expert view piece, Ed Corbett, engagement manager at specialist management consultancy firm Novasecta, explores the different routes British pharma giant GSK might take to ensure its next wave of growth. 18 August 2016
Canada-based drugmaker Valeant Pharmaceuticals' share price soared by more than a quarter on Tuesday – despite missing analyst predictions in its quarterly results. 10 August 2016
It was a grim Monday morning for Ireland-incorporated company Allergan as its share price slid by nearly 3% in early trading after posting quarterly results which did not deliver the revenue returns which analysts expected. 8 August 2016
More than 9% was wiped off the value of Novo Nordisk’s share price on Friday as the Danish diabetes giant reduced its sales and profit estimates for the year. 5 August 2016
Bosses at Teva Pharmaceutical Industries remain confident in its ability to deliver multi-year growth despite a slight dip in sales in its generics business in this year’s second quarter compared to the same period of 2015. 4 August 2016
German science and technology company Merck KGaA (MRK: DE) reported an 18.2% increase in net sales to 3.8 billion euros ($4.2 billion) in its second quarter results. 4 August 2016
Shares in Anglo-Irish drugmaker Shire Pharmaceuticals rose 2.8% after the company upgraded its profit forecasts on the back of positive second quarter results. 2 August 2016
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
USA-based Kailera Therapeutics today announced its launch as a clinical-stage biopharmaceutical company focused on advancing a broad pipeline of next-generation therapies for the treatment of obesity and related conditions. 1 October 2024
Boston, USA-based biotech Aktis Oncology, which is targeting alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced the successful closing of an oversubscribed and upsized $175 million Series B financing. 1 October 2024
Chicago, USA-based ARCH Venture Partners revealed it has closed the ARCH Venture Fund XIII, a venture capital fund with more than $3 billion to support the founding and growth of early-stage biotechnology companies. 27 September 2024
USA-based biotech funder and incubator Flagship Pioneering yesterday unveiled Mirai Bio, a company pioneering the first open end-to-end platform for the biotech industry to enable the co-creation of fully optimized genetic medicines. 27 September 2024
The UK government has released a position paper outlining its vision for Framework Programme 10 (FP10), a successor to Horizon Europe, the EU's flagship research collaboration program. 26 September 2024
Italian biotech Genespire—which is developing off-the-shelf gene therapies for pediatric patients affected by genetic diseases—has announced the closing of a 46.6 million euros ($52 million) Series B financing. 25 September 2024
Healthcare plan provider Centivo has raised $75 million in equity and debt financing to support its goal of offering affordable care to employees and their families. 25 September 2024
Rare disease firm bluebird bio has announced a company-wide restructuring aimed at cutting costs by 20% and achieving quarterly cash flow break-even by the second half of 2025. 25 September 2024
Aptadir Therapeutics, a biotech company focused on RNA inhibitor-based therapies for cancer and genetic conditions, has launched with $1.6 million in pre-seed funding. 24 September 2024
Australian biotech company Telix Pharmaceuticals is to acquire USA-based RLS Radiopharmacies, expanding its manufacturing and distribution footprint in North America. 24 September 2024
British biotech Vicebio has secured $100 million in a series B funding round to accelerate the development of its next-generation vaccines against respiratory viruses. 23 September 2024
A pre-clinical stage biopharmaceutical group developing new medicines and treatments to treat blood and autoimmune disease and to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases.
Sign up to receive email updates Join industry leaders for a daily roundup of biotech & pharma news